(Q48036622)

English

Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.

scientific article published on 20 September 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17070628%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17070628%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Plasmodium falciparum

0 references

Angel M. Carcaboso

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17070628%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Rosa Maria Hernandez

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17070628%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17070628%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

author name string

Mata E

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17070628%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Corradin G

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17070628%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Pedraz JL

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17070628%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

language of work or name

0 references

publication date

20 September 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17070628%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17070628%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17070628%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17070628%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

877-885

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17070628%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Between hope and a hard place

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

The economic and social burden of malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Where did it all go wrong?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Malaria vaccine developments

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Progress and challenges for malaria vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Peptide-based subunit vaccines against pre-erythrocytic stages of malaria parasites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

4th meeting on Novel Adjuvants Currently in/close to Human Clinical Testing World Health Organization -- organisation Mondiale de la Santé Fondation Mérieux, Annecy, France, 23-25, June 2003

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

What are the limits of adjuvanticity?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Recent developments in vaccine delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Encapsulation in biodegradable microparticles enhances serum antibody response to parenterally-delivered beta-amyloid in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Induction of cytotoxic T-cell responses following oral immunization with synthetic peptides encapsulated in PLG microparticles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL peptide entrapped in biodegradable polymer microspheres

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Immune responses to a GnRH-based anti-fertility immunogen, induced by different adjuvants and subsequent effect on vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

In vitro degradation study of polyester microspheres by a new HPLC method for monomer release determination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Intrinsically unstructured proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Antigenic cross-reactivity between different alleles of the Plasmodium falciparum merozoite surface protein 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Measurement of protein using bicinchoninic acid

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

A prime-boost regime that combines Montanide ISA720 and Alhydrogel to induce antibodies against the HIV-1 derived multiepitope polypeptide TAB9

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Induction of a cytotoxic T-cell response to HIV-1 proteins with short synthetic peptides and human compatible adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Enhancing immunogenicity and reducing dose of microparticulated synthetic vaccines: single intradermal administration.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

An investigation of the intradermal route as an effective means of immunization for microparticulate vaccine delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Genetic diversity and antigenic polymorphism in plasmodium falciparum: Extensive serological cross-reactivity between allelic variants of merozoite surface protein 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Pathways and strategies for developing a malaria blood-stage vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Strain-specific humoral response to a polymorphic malaria vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Naturally acquired antibodies to the glutamate-rich protein are associated with protection against plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Influence of adjuvant formulation on the induced protection of mice immunized with total soluble antigen of Trichinella spiralis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Induction and regulation of the IgE response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Duffy binding protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

Aluminium adjuvants--in retrospect and prospect

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.09.036

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2006.09.036

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17070628%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17070628%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48036622&oldid=2094436908"